Plasmagen Biosciences taps into the niche Indian Biopharmaceutical market with the launch of CSL’s Haemocomplettan® P


Haemocomplettan® P will cater to the 1,50,000 cardiac surgeries and over 1,800 liver transplant patients who are at risk of massive bleeding due to acquired hypofibrinogenemia

Mumbai (Maharashtra) [India], 25th June 2024: Plasmagen Biosciences Private Limited (“Plasmagen”), the Indian biopharmaceutical organization, headquartered in Bengaluru, specializing exclusively in Plasma Protein and Speciality Care Therapy, has recently announced the launch of Haemocomplettan® P (Human Fibrinogen Concenrate), manufactured by CSL Behring, a business unit of global biotechnology leader CSL. Plasmagen is CSL Behring’s exclusive distributor of Haemocomplettan® P in India. Haemocomplettan® P is approved for therapy and prophylaxis of haemorrhagic diatheses in congenital afibrinogenaemia and acquired hypofibrinogenaemia.

Due to the high burden of uncontrolled massive bleeding in cardiac and liver transplant surgeries, there is an immense need for a product like Haemocomplettan® P in India. Therefore, Plasmagen pursues a vision of ushering in these niche therapy segments with products like Haemocomplettan® P. With approximately 1,50,000 cardiac surgeries and around 1,800 liver transplants being performed in India every year, there is a huge need for such therapies in the country. Approximately 1 out of every 2 cardiac surgery patients requires blood transfusion to manage haemorrhage, and over 25% of blood transfusions in hospitals are for liver transplant recipients and Haemocomplettan® P could be used specially for massive haemorrhagic cases.

Delayed control of massive bleeding during cardiac surgery can result in irreversible end-organ damage like renal failure, cardiovascular events like stroke and myocardial injury or even death, accompanied by significantly inflated costs. Massive bleeding and excessive blood transfusion in liver transplant can result in prolonged ICU/Hospital stay, more septic episodes and higher mortality rate. Fibrinogen rapidly restores haemostasis by providing convenient replacement therapy in patient with massive bleeding and fibrinogen deficiency. CSL Behring- manufactured Haemocomplettan® P is a purified human fibrinogen concentrate, which has an experience of over 27 years and over 3.5 lakh patients treated worldwide.

“Fibrinogen plays a pivotal role in cardiac surgery bleeding, with decreased concentrations contributing to adverse outcomes. Human fibrinogen concentrate (HFC) has demonstrated efficacy in restoring fibrinogen levels, offering potential benefits in reducing bleeding and minimizing the need for intraoperative blood transfusions”, said Dr. N Kanagarajan, Senior Consultant Cardiac Anaesthesiologistat the Madras Medical Mission, Chennai.

“The Collaboration of Plasmagen and CSL Behring will not only further open new avenues in different specialties which includes Cardiac, Liver Transplant, Gastroenterology and Pediatrics but also ensure access to quality products with global safety standards in the biopharmaceutical space. We are also committed towards providing holistic solutions in therapy shaping, disease awareness and patient education”, said Mr. Vinod Nahar, Managing Director, Plasmagen Biosciences.